Background: Classical allergen-specific immunotherapy (SIT), using subcutaneous injections with food extracts, may be effective but dangerous due to anaphylactic side-effects. The FAST project (Food Allergy Specific Immunotherapy) aims at the development of safe and effective treatment of food allergies, targeting persistent and severe allergy to fish (cod) and fruit (peach). Both are caused by a single major allergen, parvalbumin (Cyp c 1) and lipid transfer protein (Pru p 3), respectively. FAST will apply hypoallergenic recombinant major allergens for SIT. Methods: Two approaches were evaluated for achieving hypo-allergenicity, i.e. site-directed mutagenesis and chemical modification. Wildtype (wt) natural and recombinant allergens and the hypo-allergens were extensively purified and characterized physico-chemically. Their stability was tested and allergenicity was compared by CAP-inhibition and histamine release experiments while immunogenicity was tested in T-cell proliferation experiments and rabbit and mice immunizations. Results: For Cyp c 1, the mutant without calcium-binding site showed up to a 1000 times reduced allergenicity, while secondary fold and immunogenicity (tested in human PBMC stimulations and by immunization of laboratory animals) were retained. Chemically modified Cyp c 1 demonstrated a reduced capacity to stimulate T-cells and showed less immunogenicity in rabbits. The calcium-binding mutant has been produced under GMP conditions.For Pru p 3, 5 potential hypoallergens were compared. The allergenicity was reduced to a similar extent (w1000-fold) for both variants in which disulfide bridges were disrupted, i.e. either by mutagenesis or by reduction/alkylation. The modification resulted in loss of alpha-helical secondary structure. However, unexpectedly, the immunogenicity was also significantly lowered/absent. Conclusions: For the Cyp c 1 calcium-binding mutant we are preparing to enter Phase I clinical trials. For Pru p 3, we need to evaluate new molecules to generate a hypoallergenic mutant that retains immunogenicity.
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IFN-ã Induces Milk Allergen-Specific IL-10-Producing Regulatory B Cells in Non-IGE Mediated Milk Allergy
Jae Ho Lee, Sr, MD, PhD. Department of Pediatrics, School of Medicine, Chungnam National University, Taejeon, South Korea. Background: Tolerance induction is one of the most important concerns in the treatment of allergies and autoimmune diseases. L-10-producing regulatory B cells (Br1s) seem to have a role in immune tolerance to food allergens. Oral immunotherapy using IFN-gamma has been successful for food allergy treatmen. We were to investigate the effects of IFN-gamma on allergen-specific Br1 responses in milk allergy patients and milk-tolerant subjects to evaluate the mmunomodulatory effects of IFN-gamma on Br1 cell responses. Methods: The 6 milk allergy patients and 8 milk-tolerant subjects were selected by DBPCFC and clinical characteristics. The PBMCs were stimulated in vitro with casein only, IFN-gamma with casein, or without any stimulant. And the CD19(1) CD5(1) B cells were gated and the expression of IL-10 and Annexin V binding were subsequently analysed. Results: In milk allergy group, the Br1 fraction decreased from 24.4 to 15.0% (P ¼ 0.002) after casein stimulation and it was recovered to 22.6% in the presence of IFN-gamma (P ¼ 0.006). In milk-tolerant group, the Br1 fraction increased from 9.4 to 17.1% after casein stimulation (P ¼ 0.014) and to 15.7% after IFNgamma were added (P ¼ 0.066). The proportion of apoptotic Br1s among CD5 (1) B cells decreased from 16.5 to 8.1% with casein (P ¼ 0.003) and to 11.8% with IFN-gamma and casein (P ¼ 0.141) in milk allergy group, while in milktolerant group, the proportion of apoptotic Br1 increased from 8.2 to 15.0% after casein stimulation (P ¼ 0.014), but was unchanged by casein with IFN-gamma. Conclusions: Allergen-specific Br1 responses and the apoptotic Br1 fraction were induced by IFN-gamma in milk allergy patients, but were not changed in milk-tolerant subjects. Finally IFN-gamma induced allergen-specific Br1 responses and immune tolerance to specific allergens in milk allergy patients. 
